News
Xeljanz/Xeljanz XR Approved for Active Ankylosing Spondylitis
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19